YAVNE, Israel, Sept. 14, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that a "Meet the Expert" panel chaired by BMO Capital Markets and comprised of leading burn specialists from across Europe will be convened at the upcoming 16th European Burns Association (EBA) Congress on September 17th at 1:00 p.m. Eastern time. The Congress is taking place September 16-19, 2015 at the Convention Center in Hanover, Germany.
Investors and other interested parties can access the panel discussion by dialing (877) 280-1254 (US) and entering passcode 5440265. The audio of the panel discussion will be broadcast live on the Internet at www.mediwound.com, where it will also be archived for 90 days. A telephone replay of the panel discussion will be accessible two hours after its completion until 7:00 p.m. Eastern time September 23, 2015 by dialing (866) 932-5017 and entering passcode 5440265.
The panel discussion will be chaired by BMO Capital Markets analyst Kathryn Brennan, and will share outcomes from the growing use of NexoBrid® throughout Europe for debridement of severe burns. The panel will include the following leading burn experts from across Europe:
- Antonio Di Lonardo, M.D., Azienda Ospedaliero Universitaria (Pisa, Italy)
- Frederik Huss, M.D., Akademiska Sjukhuset (Uppsala, Sweden)
- Jan Koller, M.D., University Hospital (Bratislava, Slovakia)
- José Ramón Martínez, M.D., H.U. La Paz (Madrid, Spain)
- Stan Monstrey, M.D., Universitair Ziekenhuis (Gent, Belgium)
- Frank Sander, M.D., Unfallkrankenhaus (Berlin, Germany)
"We greatly appreciate the participation of these renowned physicians, who will share their hands-on experience using NexoBrid to treat their severe burn patients and address live questions from investors and other interested parties. We are particularly pleased with the stature of the participants, each a pillar in burn care in his country, as well as the variety of countries and institutions represented. We believe these various perspectives will provide a valuable exchange of information and insight on NexoBrid's impact from all across Europe," stated Gal Cohen, President and Chief Executive Officer of MediWound. "We thank the burn specialists in the panel for making themselves accessible to the audience and BMO for initiating and hosting the event. We look forward to an enlightening discussion and to continuing our work in expanding access to NexoBrid to patients with severe burns across Europe."
About the European Burns Association
The European Burns Association (EBA) is a non-profit organization dedicated to the promotion of burn prevention, the study of the prevention of burn injury and all aspects of burn treatment. It also serves as a resource to facilitate communication and collaboration between burn care specialists. An exchange of information between the various burn centers in Europe will help the EBA to promote its goals. The purpose of the Congress is to bring medical specialists, researchers, paramedics, nurses and other workers in contact to discuss aspects of burn treatment and research.
NexoBrid is an easy-to-use, topically-applied pharmaceutical product that removes dead or damaged tissue, known as eschar, in four hours without harming the surrounding healthy tissues. NexoBrid was granted marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, and has been launched in Europe and Israel. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or "debridement" is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard-of-care (SOC), burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency and from the Israeli Ministry of Health for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, clinical trials and the regulatory authorizations. Forward-looking statements are based on MediWound's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the FDA or the EMA regulatory approval process or additional competition in the market. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
|Contacts:||Anne Marie Fields|
|Sharon Malka||Senior Vice President|
|Chief Financial & Operation Officer||LHA|